Efficacy and safety of the Russian GLP-1 receptor agonist Quincenta (semaglutide) in patients with type 2 diabetes mellitus in real clinical practice (QUINPROMIS study. Interim data)

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Background. Type 2 diabetes mellitus (DM2) is a socially significant disease with a constant growth trend. Therefore, the issues of personalized therapy using innovative drugs are especially relevant given their impact on various factors of the disease pathogenesis. Early prescription of adequate therapy and achievement of the treatment goal according to the indicators of the carbohydrate spectrum of the blood, weight loss are important factors in the prevention of cardiovascular diseases. Continuing research in this area may improve the quality of life of DM 2patients with T2DM.

Objective. Evaluation of the efficacy and safety of using semaglutide (Quincenta®) in the QUINPROMIS study on metabolic status indicators in DM2 patients in routine clinical practice.

Methods. The study included 30 patients of both sexes aged 40 to 65 years inclusive, with a confirmed diagnosis of DM2 lasting at least 6 months, who had not achieved target carbohydrate metabolism control indicators on metformin therapy at a total daily dose of ≥ 1500 mg, which had to be stable for 8–12 weeks before inclusion in the study. Semaglutide was added to metformin therapy in all patients. Patients underwent standard studies, glycated hemoglobin and blood glucose levels were determined. Body weight, waist and hip circumference were assessed.

Results. Patients included in the study had a relatively short duration of diabetes, were characterized by poor glycemic control, and were obese. During combination therapy, there was a decrease in glycemia from 8,01 to 6,88 mmol/l (P = 0,0034), glycated hemoglobin levels from 7,49 to 6,38% (P < 0.0001), body weight from 101,1 to 94,27 kg (P = 0,0627), waist circumference from 116,33 to 109,23 cm (P = 0,0132), hip circumference from 117,64 to 113,2 cm (P = 0,0243).

Conclusion. The use of innovative approaches to therapy allowed to improve compensation of carbohydrate metabolism, reduce body weight in DM2 patients during therapy with metformin in combination with semaglutide. Additional experience with the use and confirmation of the safety of semaglutide in DM2 patients was obtained.

全文:

受限制的访问

作者简介

M. Antsiferov

Endocrinology Dispensary of the Moscow Healthcare Department; Russian Medical Academy of Continuous Professional Education

Email: cifrenda@yandex.ru
ORCID iD: 0000-0002-9944-2997
SPIN 代码: 1035-4773
俄罗斯联邦, Moscow; Moscow

O. Koteshkova

Endocrinology Dispensary of the Moscow Healthcare Department

Email: cifrenda@yandex.ru
ORCID iD: 0000-0001-8428-4116
SPIN 代码: 6141-1224
俄罗斯联邦, Moscow

D. Antsiferova

Endocrinology Dispensary of the Moscow Healthcare Department; Russian Medical Academy of Continuous Professional Education

编辑信件的主要联系方式.
Email: cifrenda@yandex.ru
ORCID iD: 0000-0002-3920-5914

Endocrinologist; Postgraduate Student at the Department of Endocrinology

俄罗斯联邦, Moscow; Moscow

L. Romashkina

Endocrinology Dispensary of the Moscow Healthcare Department

Email: cifrenda@yandex.ru
俄罗斯联邦, Moscow

Yu. Golubeva

Endocrinology Dispensary of the Moscow Healthcare Department

Email: cifrenda@yandex.ru
俄罗斯联邦, Moscow

参考

  1. Дедов И.И., Шестакова М.В., Викулова О.К. и др. Эпидемиологические характеристики сахарного диабета в Российской Федерации: клинико-статистический анализ по данным регистра сахарного диабета на 01.01.2021. Сахарный диабет. 2021;24(3):204–21. [Dedov I.I., Shestakova M.V., Vikulova O.K., Zheleznyakova A.V., Isakov M.А. Epidemiological characteristics of diabetes mellitus in the Russian Federation: clinical and statistical analysis according to the Federal diabetes register data of 01.01.2021. Diabetes mellitus. 2021;24(3):204-221. (In Russ.)]. doi: 10.14341/DM12759.
  2. Williams R., Colagiuri S., Chan J., et al. International Diabetes Federation. IDF Diabetes Atlas. 9th ed. Brussels, Belgium. 2019.
  3. Дедов И.И., Шестакова М.В., Галстян Г.Р. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет. 2016;19(2):104–12. [Dedov I.I., Shestakova M.V., Galstyan G.R. The prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study). Diabetes mellitus. 2016;19(2):104-112. (In Russ.)]. doi: 10.14341/DM2004116-17
  4. Мкртумян А.М., Егшатян Л.В. Эффективность семаглутида в свете доказательной медицины. Медицинский совет. 2023;17(6):264–73. [Mkrtumyan AM, Egshatyan LV. Efficacy of semaglutide: an evidence-based review. Meditsinskiy sovet = Medical Council. 2023;(6):264–73. (In Russ.)]. doi: 10.21518/ms2022-010.
  5. Rodbard H.W., Lingvay I., Reed J., et al. Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial. J Clin Endocrinol Metab. 2018;103(6):2291–301. doi: 10.1210/jc.2018-00070
  6. Данные регистра сахарного диабета ГНЦ РФ ФГБУ «НМИЦ эндокринологии» Минздрава России. Электронный ресурс: URL: https://sd.diaregistry.ru/?ysclid = m4a0v4yv8h133819048 Свободный доступ. [Data from the diabetes registry of the Russian State Research Center of Endocrinology of the Russian Ministry of Health. Electronic resource: URL: https://sd.diaregistry.ru/?ysclid = m4a0v4yv8h133819048 (In Russ.)]. Free access.
  7. Аметов А.С., Цыганкова О.В. Комплексная метаболическая протекция как современная стратегия управления сахарным диабетом 2 типа. Эндокринология: новости, мнения, обучение. 2021;10(2):93–104. [Ametov A.S., Tsygankova O.V. Complex metabolic protection as a modern strategy for the management of type 2 diabetes mellitus. Endokrinologiya: novosti, mneniya, obuchenie = Endocrinology: News, Opinions, Training. 2021;10(2):93–104. (In Russ.)]. doi: 10.33029/2304-9529-2021-10-2-93-104.
  8. Ahren B., Atkin S.L., Charpentier G., et al. Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. Diab Obes Metab. 2018;20(9):2210–9. doi: 10.1111/dom.13353.
  9. Sorli C., Harashima S.I., Tsoukas G.M., et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet. Diab Endocrinol. 2017; 5(4):251–60. doi: 10.1016/S2213-8587(17) 30013-X.
  10. Ahren B., Masmiquel L., Kumar H., et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet. Diab Endocrinol. 2017;5(5):341–54. Doi: /10.1016/S2213-8587(17)30092-X.
  11. Ahmann A.J., Capehorn M., Charpentier G., et al. ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. Diab Care. 2018;41(2):258–66. doi: 10.2337/dc17-0417.
  12. Aroda V.R., Bain S.C., Cariou B., et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as addon to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet. Diab Endocrinol. 2017;5(5):355–66. doi: 10.1016/S2213-8587(17)30085-2.
  13. Rodbard H.W., Lingvay I., Reed J., et al. Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial. J Clin Endocrinol Metab. 2018;103(6):2291–301. doi: 10.1210/jc.2018-00070.
  14. Marso S.P., Bain S.C., Consoli A., et al.; SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834–44. doi: 10.1056/NEJMoa1607141.
  15. Pratley R.E., Aroda V.R., Lingvay I., et al.; SUSTAIN 7 investigators. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet. Diab Endocrinol. 2018;6(4):275–86. doi: 10.1016/S2213-8587(18)30024-X.
  16. Lingvay I., Catarig A.M., Frias J.P., et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet. Diab Endocrinol. 2019;7(11):834–44. doi: 10.1016/S2213-8587(19)30311-0.
  17. Zinman B., Bhosekar V., Busch R., et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet. Diab Endocrinol. 2019;7(5):356–367. doi: 10.1016/S2213-8587(19)30066-X.
  18. Capehorn M.S., Catarig A.M., Furberg J.K., et al. Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diab Metab. 2020;46(2):100–9. doi: 10.1016/j.diabet.2019.101117.
  19. Дедов И.И., Шестакова М.В., Майоров А.Ю. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 11-й выпуск. Сахарный диабет. 2023;26(2S):1–157. [Dedov I.I., Shestakova M.V., Mayorov A.Yu., et al. Algorithms of specialized medical care for patients with diabetes mellitus. Ed. by I.I. Dedov, M.V. Shestakova, A.Yu. 11th issue. Diabetes mellitus. 2023;26(2S):1–157. (In Russ.)]. Doi: 10.14341/ DM13042.
  20. Аметов А.С., Шохин И.Е., Рогожина Е.А. и др. Сравнительный анализ физико-химических свойств, биоэквивалентности, безопасности и переносимости отечественного семаглутида. Фармация и фармакология. 2023;11(4):324–46. [Ametov A.S., Shokhin I.E., Rogozhina E.A., et al. Comparative analysis of physicochemical properties, bioequivalence, safety and tolerability of the first domestic semaglutide. Pharmacy & Pharmacology. 2023;11(4):324–46. (In Russ.)]. doi: 10.19163/2307-9266-2023-11-4-324-346.
  21. Трошина Е.А., Ершова Е.В. Фармакотерапия ожирения: что нового? Проблемы эндокринологии. 2018;64(4):270–6. [Troshina E.A, Ersho-va E.V. Pharmacotherapy o obesity: what’s new? Problems of Endocrinology. 2018;64(4):270–76. (In Russ.)]. doi: 10.14341/probl9315.

补充文件

附件文件
动作
1. JATS XML
下载
2. Fig. 1. Schematic diagram of the study

下载 (117KB)
索引源数据
3. Fig. 2. Dynamics of GPN level (mmol/l) from B1 to B4 when using Quincenta® (p = 0.0034)

下载 (32KB)
索引源数据
4. Fig. 3. Dynamics of HbAlcc B1 to B4 levels when using the drug Quincenta® (p < 0.0001)

下载 (28KB)
索引源数据
5. Fig. 4. Dynamics of body weight from B1 to B4 when using Quincenta® (p = 0.0627)

下载 (33KB)
索引源数据
6. Fig. 5. Percentage of patients who achieved weight reduction from B1 to B4 when using Quincenta® preparation

下载 (38KB)
索引源数据
7. Fig. 6. Dynamics of waist circumference from B1 to B4 when using Quincenta® (p = 0.0132)

下载 (37KB)
索引源数据
8. Fig. 7. Dynamics of hip circumference from B1 to B4 with Quincenta® (p = 0.0243)

下载 (33KB)
索引源数据

版权所有 © Bionika Media, 2024